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Setting of a Multicenter Randomized Controlled Trial: Can the
Operator Experience Affect the Study Results?
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Background-—Operator experience inﬂuences outcomes after percutaneous coronary intervention, but this association in the
controlled setting of a randomized, clinical trial is unclear.
Methods and Results-—We investigated operator-related outcomes (30-day and 2-year efﬁcacy and safety end points) among
patients undergoing percutaneous coronary intervention and randomized to different dual antiplatelet therapy durations and stent
types. A total of 2003 patients were analyzed, and 7 operator groups were compared. The majority of preprocedural and
postprocedural characteristics were imbalanced. The primary end point of the study, the composite of death, myocardial infarction,
or cerebrovascular accidents, did not differ among operators at 30 days or 2 years. There were no signiﬁcant differences also for
all other individual and composite end points analyzed at 30 days and 2 years, except for 2-year stent thrombosis (P=0.048) and
bleeding events (P=0.022 for Bleeding Academic Research Consortium type 2, 3, or 5). Adjusted comparisons for the main end
points showed slight differences among operators at 30 days, but not at 2 years. There was no interaction of operator with dual
antiplatelet therapy duration (P=0.112) or stent type (P=0.300). Results remained entirely consistent when operators were
stratiﬁed by their experience.
Conclusions-—There was a weak signal of heterogeneity across study operators for the 30-day, but not the 2-year, main study
outcomes. No clear effect of operator or operator experience was observed for the comparative efﬁcacy and safety proﬁle of the
randomized stent types or dual antiplatelet therapy duration regimens.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00611286. ( J Am Heart Assoc. 2017;6:
e007150. DOI: 10.1161/JAHA.117.007150.)
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O wing to innovations in device technology and improvedoperator techniques, percutaneous coronary interven-
tion (PCI) has become a widely used and reproducible
therapeutic procedure for the entire spectrum of coronary
artery disease.1,2
Complications during and after PCI have dramatically
declined during the past decades. Yet, periprocedural and
postprocedural ischemic and bleeding adverse events still
occur in a sizable proportion of patients. Although patient-
related factors are known to play a key role for those
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occurrences, it is currently unknown to which degree these
adverse events may be also operator dependent. Overall
number of procedures performed and the operator experience
may affect outcomes of patients undergoing PCI, but this
evidence is mainly based on observational studies.1–11
Randomized, controlled trials have played a major role in
informing the community on the incidence, predictors, and
implications of PCI-related adverse events. However, although
the role of the center is often investigated or at least
accounted for as a source of heterogeneity for the primary
end point results, little is known on the potential impact of
different operators on results of PCI studies. Operator
expertise and the potential impact on outcomes has recently
become a contentious topic for studies assessing access
site.12–16 Whether operators may also affect outcomes of
studies assessing the performance of various stent platforms
or durations of dual antiplatelet therapy (DAPT) after coronary
stenting remains unclear. This analysis is frequently hampered
by lack of proper data collection or inclusion of few cases by
each single operator.
The aim of this study is to investigate whether an
interoperator performance variation may exist in terms of
efﬁcacy and safety in the setting of the all-comer PRODIGY
(Prolonging Dual Antiplatelet Treatment After Grading Stent-
Induced Intimal Hyperplasia Study; NCT00611286) where
patient recruitment was carried out by few interventional
cardiologists, each recruiting a high number of patients.
Methods
The design and main ﬁndings of the PRODIGY trial have been
previously reported.17–19 PRODIGY is a 4-by-2 randomized,
multicenter, open-label clinical trial designed to evaluate the
efﬁcacy and safety of prolonging the duration of clopidogrel
therapy for up to 24 months in all-comer patients receiving a
balanced mixture of stents with various anti-intimal hyper-
plasia potency and belonging to both ﬁrst- and second-
generation drug-eluting stent. Brieﬂy, all-comer PCI patients
(n=2013) were randomly allocated in a 1:1:1:1 fashion to 1 of
4 stent types, including everolimus-eluting stent, paclitaxel-
eluting stent, zotarolimus-eluting Endeavor Sprint stent, or
thin-strut bare metal stent. Patients alive at 30 days (n=1970)
were then randomly allocated to either 6 or 24 months of
DAPT. Selection criteria were broad, reﬂecting routine clinical
practice. Randomization to 6- or 24-month DAPT was
stratiﬁed by center, ongoing ST-segment-elevation myocardial
infarction, presence of diabetes mellitus, and need for
intervening for at least 1 in-stent restenotic lesion. The study
was conducted in accord with the principles of the Declara-
tion of Helsinki. The Ethics Committees of the 3 participating
centers independently approved the protocol, and all partic-
ipants gave written informed consent.
Operators
Interventional cardiologists of the 3 participating centers were
trained operators, each with >500 cumulative PCI volume as
ﬁrst operator and all involved in the 24-hour on-call duty
schedule at their referral institutions. During the trial, 6
operators performed PCI in the majority of patients enrolled,
with each treating more than 50 patients. For the present
study, each of them will represent an independent group. In
order to explore the effect of PCI experience, operators were
also further stratiﬁed in “More Experienced” and “Experi-
enced” based on: (1) number of active years as ﬁrst operator,
(2) overall PCI volume, and (3) PCI volume/year in the 2 years
before the trial initiation. “More experienced” operators were
Clinical Perspective
What Is New?
• Observational studies suggest that operator volume/expe-
rience inﬂuences outcomes after percutaneous coronary
intervention, but this is poorly explored in randomized,
clinical trials, and there is ongoing debate on whether
operator experience may inﬂuence reliability of trials
ﬁndings.
• We compared operators in PRODIGY (Prolonging Dual
Antiplatelet Treatment After Grading Stent-Induced Intimal
Hyperplasia Study), a 4-by-2 randomized multicenter all-
comer percutaneous coronary intervention trial comparing 4
stent types and 2 dual antiplatelet therapy duration
regimens.
• We observed imbalances in the patient’s and procedural
characteristics and found weak differences in rates of
clinical outcomes.
• After adjustment, there was a weak signal of heterogeneity
across operators for 30-day, but not 2-year, main outcomes.
• When operators were stratiﬁed by their experience, no
effect on clinical outcomes was observed.
What Are the Clinical Implications?
• No signiﬁcant interactions were found between operators or
operator experience and randomized dual antiplatelet
therapy duration or stent type; thus, overall ﬁndings of the
trial remained consistent.
• A prolonged dual antiplatelet therapy regimen failed to
improve outcomes, irrespective of the operators.
• The routine collection of high-quality data sets should be
encouraged to evaluate and improve operator competence
and to allow investigation of operator as effect modiﬁer of
ﬁndings, especially for short-term outcomes after percuta-
neous coronary intervention, even in the controlled setting
of a randomized, clinical trial.
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those with >5 years, >1000 overall PCI, and >75 PCI/year,
whereas “Experienced” were those with <5 years, 500 to
1000 overall PCI, and <75/year. Few other operators
performed less than 50 procedures each, thus they were
pooled in the seventh group named “other operators” overall
including 142 patients/procedures (Figure 1).
Treatment Protocol and Follow-up
All patients received aspirin (80–160 mg orally indeﬁnitely)
and clopidogrel (75 mg/day) according to the randomization
scheme as follows: for either 6 months in the short DAPT arm
or 24 months in the prolonged DAPT arm irrespective of the
previously implanted stent type or indication for PCI.
The randomized patients returned for study visits at
30 days and then every 6 months up to 2 years. During
follow-up visits, patients were examined and assessed for
adverse events, asked for the antiplatelet therapy compliance,
and 12-lead ECG recordings were obtained.
Study End Points
The primary efﬁcacy end point of the PRODIGY trial was the
composite of death, MI, or cerebrovascular accident, whereas
the key safety end point included Bleeding Academic
Research Consortium (BARC) type 2, 3, or 5 bleeding. The
net effect on the combined ischemic and bleeding complica-
tions was obtained by 2 net adverse clinical event (NACE) end
points that were generated by combining the primary efﬁcacy
end point of death, MI, or cerebrovascular accident with either
the primary safety end point of BARC type 2, 3, or 5 bleeding
or with BARC type 3 or 5 events. Other end points included
each component of the primary efﬁcacy end point, cardio-
vascular death, stent thrombosis (ST) deﬁned on the basis of
the Academic Research Consortium criteria, and BARC type 3
or 5 bleeding. Other safety end points included bleeding
events adjudicated according to the thrombolysis in myocar-
dial infarction and global use of strategies to open occluded
coronary arteries scales. All study end point deﬁnitions were
previously reported.
All end points were conﬁrmed on the basis of documen-
tation collected at each hospital and were centrally adjudi-
cated by the clinical events committee, whose members were
unaware of the patients’ treatment-group assignments. The
time frame of interest for the primary end point was from
30 days (ie, after the primary end point randomization) to
24 months.
Statistical Analysis
The PRODIGY trial was designed to enroll at least 1700
patients to detect a 40% reduction in the relative risk of the
primary end point in the 24-month clopidogrel group
compared with 6-month duration of clopidogrel therapy, with
statistical power of >80% at a 2-sided signiﬁcance level of
0.05. The planned sample size was ﬁnally increased up to
2000 to allow for fatalities occurring within the ﬁrst 30 days,
noncompliance, and loss to follow-up as previously
described.17–19
Categorical variables were expressed as frequency (per-
centage), whereas continuous variables were expressed as
mean and SD. Baseline and procedural characteristics among
503
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Figure 1. Operator procedure distribution.
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the 7 groups were compared using chi-square test for
categorical variables and ANOVA F test for continuous
variables. Crude events among groups were compared with
likelihood ratio P values testing the shared frailty effect across
operators using an inverse gamma distribution in Weibull
time-to-event regression. Estimation of the cumulative major
adverse cardiovascular event (MACE) rate, as well as of BARC
bleeding and NACE, was performed by the Kaplan–Meier
method.
In order to compare clinical outcomes among groups,
hazard ratios with 95% conﬁdence intervals were calculated
from adjusted Weibull time-to-event regression comparing
each operator (operator 2 to operator 6) versus operator 1
who was elected as reference because of the highest number
of patients/procedures performed. The adjustment was
performed including the following variables: age, sex, body
mass index, hypertension, dyslipidemia, current smoking,
family history of coronary artery disease, previous PCI,
previous coronary artery bypass graft, peripheral arterial
disease, creatinine clearance, left ventricular ejection fraction,
acute coronary syndrome, femoral access, multivessel PCI,
PCI performed by 2 or more operators (versus 1 operator
only), 1 or more complex lesions, 1 or more restenotic lesions,
randomized stent (4 categories), total stent length, and
CRUSADE (Can Rapid risk stratiﬁcation of Unstable angina
patients Suppress ADverse outcomes with Early implementa-
tion of the ACC/AHA Guidelines) score.
Proportional-hazards assumption was tested on the basis
of Schoenfeld residuals after ﬁtting a Cox regression model
for each of the 4 end points (P≥0.7 in each case).
Univariate analysis was conducted to explore whether
operator category may predict 2-year MACE, BARC type 2, 3,
or 5, or NACE.
Interaction testing was performed to determine whether
the effect of randomization to DAPT duration or to stent type
on the primary end point was consistent irrespective of
operator category or volume of PCI performed by each
operator.
To explore the effect of operator experience, all the
analyses were also computed contrasting “more experienced”
versus “experienced” operators on study end points.
A 2-sided probability value of <0.05 was considered
signiﬁcant. All analyses were performed with Stata Statistical
Software (release 14; StataCorp LP, College Station, TX).
Results
A total of 2013 patients were recruited into the study and
randomly assigned to 1 of the 4 stent types. Ten patients
withdrew consent. Thirty-three (1.6%) patients died within
30 days, thus 1970 patients were randomly allocated at
1 month to undergo 24-month versus 6-month duration of
clopidogrel therapy. Seven operator groups were created by
matching cases to ﬁrst treating operator as follows: operator
1 (n=503), operator 2 (n=425), operator 3 (n=373), operator 4
(n=306), operator 5 (n=157), operator 6 (n=97), and other
operators including 10 operators performing each less than
50 procedures and cumulatively recruiting 142 patients into
the study (Figure 1).
Baseline and Procedural Characteristics
Table 1 reports baseline and procedural characteristics
according to the operator groups. There were notable
imbalances across operators that were mainly driven by the
other operators group, which recruited patients who were
slightly younger, more frequently affected by stable coronary
artery disease (one fourth of patients in this group presented
acute coronary syndrome as compared with three fourths of
patients in all other operator groups), with preserved renal
and left ventricular function, and lower bleeding risk. Operator
1 treated the highest rate of past MI or ST-segment-elevation
myocardial infarction patients or those requiring more
frequently left main coronary artery intervention, or present-
ing with the mean lowest mean left ventricular ejection
fraction (Table 1). On the other hand, operator 6 treated the
highest number of lesions per procedure, with at least 1
complex lesion per procedure as well as more patients with
past coronary artery bypass graft. Multivessel or saphenous
vein graft intervention was more frequently accomplished by
operator 2, whereas operator 5 performed the lowest number
of multivessel/multilesion interventions (Table 1). Radial
access was the default access site across all operators.
Clinical Outcomes
At 30 days, there were no signiﬁcant differences among
operator groups for any analyzed individual or composite end
points (Table 2). The highest rate of the primary end point was
observed for operator 6, who experienced, however, the
lowest number of any or access-site bleeding events.
Operator 2 had the highest rate of cerebrovascular accident,
BARC bleeding, as well as NACE. Operator 1 was the one
experiencing the lowest rate of death and cerebrovascular
accident, whereas operator 5 was associated with the lowest
rate of MACE and NACE. Operator 1 and 2 were associated
with the highest rate of access-site–related bleeding
(Table 2). In the group of other operators, none of the
patients died or had stroke or ST or target vessel revascu-
larization or bleeding, and all events within 30 days were MI.
At 2-year follow-up, there were no signiﬁcant differences
among operators for the primary end point as well as the
majority of secondary end points, except for ST, mainly driven
by no event in the other operator group and for BARC type 2,
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3, or 5, mainly driven by difference for BARC 2 across
operator groups (Table 3). ST was more frequently observed
with operator 2, whereas operator 5 was associated with the
highest rate of overall and most severe bleeding events. On
the other hand, operator 5 was associated with the lowest
rate of MI, ST, and target vessel revascularization. Operator 6
was the one with highest rate of the primary end point, as well
as NACE, predominantly driven by the highest rates of death
and MI (Table 3), whereas the primary end point was lowest
for operator 3. Overall, the group of other operators who
treated more stable patients was associated with lowest rates
of death, bleeding, and composite end points (Table 3).
Adjusted comparisons for the main efﬁcacy and safety end
points at 30 days and 2 years are shown in Table 4. At
30 days, MACE and NACE were signiﬁcantly increased with
operator 2 compared with operator 1. Trends toward higher
risk of MACE (49–56%) and NACE (45–52%) were also noted
for Operator 4 and 6 as compared with operator 1, mainly
attributable to increased risk of ischemic events. At 2 years,
there was, however, no notable difference in operators’
Table 2. Clinical Outcomes at 30 Days
Event
Operator
1 (N=503)
Operator
2 (N=425)
Operator
3 (N=373)
Operator
4 (N=306)
Operator
5 (N=157)
Operator
6 (N=97)
Other
Operators
(N=142) P Value
P Value
Without
Other
Operators
Primary efficacy end point
All-cause death, MI, or CVA 46 (9.1) 54 (12.7) 35 (9.4) 38 (12.4) 13 (8.3) 13 (13.4) 18 (12.7) 0.420 0.401
Secondary efficacy end points
All-cause death or MI 45 (8.9) 47 (11.1) 34 (9.1) 37 (12.1) 12 (7.6) 12 (12.4) 18 (12.7) 1.000 1.000
All-cause death 4 (0.8) 6 (1.4) 11 (2.9) 6 (2.0) 4 (2.5) 2 (2.1) 0 (0.0) 0.211 0.279
Cardiovascular death 4 (0.8) 6 (1.4) 11 (2.9) 6 (2.0) 4 (2.5) 2 (2.1) 0 (0.0) 0.211 0.279
Stroke or TIA 1 (0.2) 8 (1.9) 2 (0.5) 1 (0.3) 3 (1.9) 1 (1.0) 0 (0.0) 0.057 0.074
Myocardial infarction 43 (8.5) 43 (10.1) 27 (7.3) 32 (10.5) 8 (5.1) 10 (10.3) 18 (12.7) 1.000 1.000
Definite ST 5 (1.0) 4 (0.9) 1 (0.3) 4 (1.3) 0 (0.0) 0 (0.0) 0 (0.0) 1.000 1.000
Definite or probable ST 7 (1.4) 6 (1.4) 4 (1.1) 7 (2.3) 1 (0.6) 1 (1.0) 0 (0.0) 1.000 1.000
Definite probable or possible ST 7 (1.4) 6 (1.4) 5 (1.4) 7 (2.3) 1 (0.6) 1 (1.0) 0 (0.0) 1.000 1.000
TVR 6 (1.2) 5 (1.2) 3 (0.8) 4 (1.3) 1 (0.7) 0 (0.0) 0 (0.0) 1.000 1.000
Safety end points
Access-site related bleeding* 8 (1.6) 7 (1.6) 2 (0.5) 2 (0.7) 1 (0.6) 0 (0.0) 1 (0.7) 0.065 0.047
BARC classification
Key safety end point—type 2, 3, or 5 12 (2.4) 10 (2.4) 5 (1.4) 5 (1.6) 3 (2.0) 0 (0.0) 0 (0.0) 1.000 1.000
Type 3 or 5 4 (0.8) 4 (0.9) 2 (0.5) 2 (0.7) 1 (0.7) 0 (0.0) 0 (0.0) 1.000 1.000
TIMI classification
Minor 3 (0.6) 1 (0.2) 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1.000 1.000
Major 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0.145 0.153
Minor or major 3 (0.6) 1 (0.2) 2 (0.5) 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 1.000 1.000
GUSTO classification
Moderate 2 (0.4) 3 (0.7) 1 (0.3) 0 (0.0) 1 (0.7) 0 (0.0) 0 (0.0) 1.000 1.000
Severe 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0.145 0.153
Moderate or severe 2 (0.4) 3 (0.7) 1 (0.3) 2 (0.7) 1 (0.7) 0 (0.0) 0 (0.0) 1.000 1.000
Net clinical adverse events (NACE)
All-cause death, MI, CVA, or BARC 2, 3, or 5 58 (11.5) 63 (14.8) 40 (10.7) 41 (13.4) 16 (10.2) 13 (13.4) 18 (12.7) 1.000 1.000
All-cause death, MI, CVA, or BARC 3 or 5 50 (9.9) 58 (13.6) 37 (9.9) 39 (12.7) 14 (8.9) 13 (13.4) 18 (12.7) 0.453 0.419
Likelihood ratio P value testing the shared frailty effect across operators using an inverse gamma distribution in Weibull time-to-event regression. BARC indicates Bleeding Academic
Research Consortium; CVA, cerebrovascular accident; GUSTO, global use of strategies to open occluded coronary arteries; MI, myocardial infarction; ST, stent thrombosis; TIA, transient
ischemic attack; TIMI, thrombolysis in myocardial infarction; TVR, target vessel revascularization.
*Access-site related bleeding analyzed with mixed effects logistic regression.
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performances. Operator category did not predict 2-year MACE
(P=0.74), BARC type 2, 3, or 5 (P=0.31), or NACE (P=0.66 and
0.85 for NACE with BARC 2, 3, or 5, and BARC 3 or 5,
respectively).
Operator Interaction With DAPT and Stent
Randomized Groups for the Primary Outcome
When the primary end point of all-cause death, MI, or
cerebrovascular accident was stratiﬁed according to the
operators, no signiﬁcant interaction emerged between oper-
ator and DAPT randomization (P=0.112; Figure 2), and this
was conﬁrmed at 6-month landmark analysis (from 6 months
to 2 years: P=0.425; Figure S1).
Similarly, interaction testing between operator and stent
type (P=0.300; Figure 2) was negative. Also, no interaction
was observed between operator and DAPT or randomized
stent at stratiﬁed analysis by operator volume (Figures S2 and
S3). Three-way interaction among operator-randomized DAPT
duration-randomized stent was similarly negative (P=0.210).
Table 3. Clinical Outcomes at 2 Years
Event
Operator
1 (N=503)
Operator
2 (N=425)
Operator
3 (N=373)
Operator
4 (N=306)
Operator
5 (N=157)
Operator
6 (N=97)
Other
Operators
(N=142) P Value
P Value
Without
Other
Operators
Primary efficacy end point
All-cause death, MI, or CVA 108 (21.5) 93 (21.9) 64 (17.2) 61 (20.0) 28 (17.8) 25 (25.8) 24 (17.0) 1.000 1.000
Secondary efficacy end points
All-cause death or MI 100 (19.9) 83 (19.5) 62 (16.6) 58 (19.0) 28 (17.8) 24 (24.8) 23 (16.2) 1.000 1.000
All-cause death 40 (8.0) 36 (8.5) 33 (8.8) 21 (6.9) 16 (10.2) 11 (11.4) 6 (4.3) 1.000 1.000
Cardiovascular death 29 (5.8) 23 (5.5) 23 (6.2) 10 (3.3) 10 (6.4) 8 (8.4) 3 (2.2) 1.000 1.000
Stroke or TIA 14 (2.9) 15 (3.6) 6 (1.7) 4 (1.4) 5 (3.2) 3 (3.2) 1 (0.7) 0.386 0.486
Myocardial infarction MI 75 (15.1) 61 (14.5) 38 (10.3) 41 (13.5) 13 (8.4) 15 (15.9) 18 (12.7) 0.349 0.300
Definite ST 11 (2.2) 10 (2.4) 2 (0.5) 6 (2.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.042 0.126
Definite or probable ST 18 (3.7) 17 (4.1) 5 (1.4) 9 (3.0) 1 (0.6) 3 (3.3) 0 (0.0) 0.048 0.195
Definite probable or possible ST 35 (7.1) 31 (7.4) 15 (4.1) 14 (4.7) 6 (3.9) 6 (6.5) 3 (2.2) 0.158 0.310
TVR 70 (14.4) 47 (11.5) 50 (14.1) 26 (8.7) 11 (7.4) 9 (10.0) 10 (7.1) 0.054 0.115
Safety end points
BARC classification
Key safety end
point—type 2, 3, or 5
39 (8.0) 40 (9.7) 25 (7.0) 16 (5.4) 16 (10.6) 5 (5.7) 1 (0.7) 0.022 0.421
Type 3 or 5 13 (2.7) 20 (4.9) 15 (4.2) 8 (2.7) 7 (4.6) 2 (2.3) 1 (0.7) 0.340 0.494
TIMI classification
Minor 9 (1.9) 7 (1.7) 6 (1.7) 1 (0.3) 1 (0.7) 2 (2.3) 0 (0.0) 1.000 1.000
Major 3 (0.6) 8 (2.0) 5 (1.4) 3 (1.0) 4 (2.6) 0 (0.0) 1 (0.7) 0.467 0.449
Minor or major 12 (2.5) 15 (3.7) 11 (3.1) 4 (1.3) 5 (3.3) 2 (2.3) 1 (0.7) 1.000 1.000
GUSTO classification
Moderate 8 (1.6) 9 (2.2) 8 (2.2) 5 (1.7) 2 (1.4) 2 (2.3) 0 (0.0) 1.000 1.000
Severe 5 (1.0) 9 (2.2) 5 (1.4) 3 (1.0) 4 (2.6) 0 (0.0) 1 (0.7) 1.000 1.000
Moderate or severe 13 (2.7) 18 (4.4) 13 (3.7) 8 (2.7) 6 (4.0) 2 (2.3) 1 (0.7) 1.000 1.000
Net clinical adverse events (NACE)
All-cause death, MI, CVA,
or BARC 2, 3, or 5
136 (27.1) 120 (28.3) 77 (20.6) 72 (23.6) 40 (25.5) 28 (29.0) 24 (17.0) 0.120 0.227
All-cause death, MI, CVA,
or BARC 3 or 5
116 (23.1) 101 (23.8) 69 (18.5) 66 (21.6) 32 (20.4) 26 (26.9) 24 (17.0) 1.000 1.000
Likelihood ratio P value testing the shared frailty effect across operators using an inverse gamma distribution in Weibull time-to-event regression. BARC indicates Bleeding Academic
Research Consortium; CVA, cerebrovascular accident; GUSTO, global use of strategies to open occluded coronary arteries; MI, myocardial infarction; ST, stent thrombosis; TIA, transient
ischemic attack; TIMI, thrombolysis in myocardial infarction; TVR, target vessel revascularization.
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Operator Experience
When analyses were conducted comparing “More experi-
enced” with “Experienced” operators, no signiﬁcant effect
emerged on clinical outcomes at 30-day or 2-year and no
interaction was noted with respect to randomized DAPT
duration or stent type (Tables S1 through S4; Figures S4 and
S5).
Discussion
The present study explored the interoperator impact on
clinical outcomes of patients undergoing PCI in the setting of
a randomized, clinical trial. Across each operator stratum,
there were several differences for patient and procedural
characteristics, making interpretation of unadjusted clinical
outcomes problematic. After adjustment, there were some
differences for 30-day outcomes, mainly owing to different
risks of ischemic events across operators. However, adjusted
analyses failed to show heterogeneous outcomes across
operator groups at 2 years, and operators did not impact on
the comparative efﬁcacy or safety proﬁle of different DAPT
durations or stent types. Therefore, the present analysis
provides reassurance that operator per se or operator
experience/operator volume was not a signiﬁcant effect
modiﬁer of our study ﬁndings.
The optimal duration of DAPT after PCI is a matter of
ongoing discussion, attributed to a clear trade-off between
beneﬁts and risks. A prolonged DAPT regimen prevents
recurrent or new MI related or not to stent thrombosis.
Furthermore, procedural complexity has emerged as an
important driver of DAPT duration, with prolonged DAPT
being beneﬁcial in more-complex procedures.20 Accordingly,
it is plausible that different operators with different technical
skills, expertise, and case volume, as well as different
procedural tactics (predilatation and postdilatation, duration
and pressure of dilatation, stent implantation sizing and
technique, use of intravascular imaging modalities, etc) may
be associated with different clinical outcomes. In this respect,
however, we did not ﬁnd signiﬁcant interaction between
operator, type of stent, and DAPT regimen, suggesting that
our overall study results were consistent across operators,
which has notable implications for the external validity of our
ﬁndings. There was, however, signal that operator may impact
events/nr of 
patients 
events/nr of 
patients 
Hazard Ratio 
(95% CI)
p-value interaction  p-value 
Randomized DAPT*: Short DAPT Long DAPT Long vs Short 
All-cause Death, MI or CVA from 30 to 720 days 0.112 
Operator 1 36/254 28/245 0.79 (0.48-1.29) 0.340 
Operator 2 16/206 27/213 1.68 (0.91-3.12) 0.099 
Operator 3 17/186 14/176 0.87 (0.43-1.76) 0.692 
Operator 4 16/150 7/150 0.41 (0.17-1.01) 0.052 
Operator 5 7/ 75 10/ 78 1.42 (0.54-3.73) 0.476 
Operator 6 5/ 45 8/ 50 1.51 (0.49-4.63) 0.468 
Other Operators*** 3/ 71 4/ 71 1.36 (0.31-6.10) 0.684 
Randomized to any DES** or BMS: DES** BMS DES vs BMS 
All-cause Death, MI or CVA from 0 to 720 days 0.300 
Operator 1 75/383 33/120 0.69 (0.46-1.04) 0.079 
Operator 2 65/316 28/109 0.80 (0.51-1.24) 0.314 
Operator 3 45/264 19/109 0.98 (0.57-1.67) 0.937 
Operator 4 49/222 12/ 84 1.59 (0.85-2.99) 0.150 
Operator 5 20/118 8/ 39 0.79 (0.35-1.80) 0.575 
Operator 6 19/ 81 6/ 16 0.61 (0.24-1.52) 0.287 
Other Operators*** 20/117 4/ 25 1.05 (0.36-3.06) 0.936 
Figure 2. Stratiﬁed effect of operators on the primary comparisons of the primary outcome in the PRODIGY trial. Hazard ratios from Weibull
time-to-event regression on the composite of all-cause death, MI, or CVA comparing the randomized DAPT durations or randomized stents and
testing for effect modiﬁcation by the Operators n (1–6). *Short DAPT randomized to 6 months of DAPT, Long DAPT randomized to 24 months of
DAPT. **ZES-S (zotarolimus-eluting Endeavor Sprint stent), PES (paclitaxel-eluting stent), and EES (everolimus-eluting stent) combined. ***The
Other Operators are shown for completeness, but not used for interaction testing. BMS indicates bare metal stent; CVA, cerebrovascular
accidents; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; MI, myocardial infarction.
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on outcomes in the early period after PCI when indeed
operator and procedural factors are more likely to play a role.
On the contrary, at 2 years, we did not observe signiﬁcant
differences across operator groups, likely as a reﬂection that
procedural technicalities adopted by each operator have
limited impact on long-term outcomes.
Physician competence is a critical component in the
provision of optimal health care. All physicians must have the
appropriate training, fund of knowledge, clinical decision
making, and technical skills. In the setting of PCI, operators
must perform these procedures at a requisite level of
proﬁciency and competency.
Patients treated by high-volume operators and at high-
volume centers have been shown to experience a higher rate
of procedural success and lower rates of mortality and
postprocedural complications.1–11 As a consequence, stan-
dards of assistance have been recommended for PCI oper-
ators.1,2,6 Recently, in an observational study, operator
experience has emerged as an important prognostic factor
in a complex intervention, such as left main PCI, where
patients treated by high-volume and experienced operators
had better outcomes.9 Operators were shown to impact on
outcomes in the setting of different complex procedures, such
as chronic total occlusions,21 the implantation of speciﬁc
devices as bioresorbable vascular scaffolds,22 and structural
interventions.23
During the past decades, the cardiology community has
been largely informed in terms of clinical practice by the
results of many randomized trials. In order to achieve enough
of a number of observations, and to reduce the bias related to
single-center studies, multicenter studies are frequently
performed and currently regarded as the study design allowing
for the greatest external validity. Multicenter PCI studies can,
however, also critically depend on expertise and proﬁciency of
the multiple operators involved. Although subgroup analyses
are frequently performed to explore the consistency of study
results across different geographical locations, and sometimes
randomization is stratiﬁed by center, the role of each operator
within each center is almost never appropriately investigated.
Operators are very rarely matched with the corresponding
treated patients within each multicenter study, and even when
this information is available, each study operator generally
contributes with a limited number of patients within each
study. There are, however, relevant exceptions. Interoperator
variation was previously investigated in 1071 patients enrolled
in the TAPAS (Thrombus Aspiration During Percutaneous
Coronary Intervention in Acute Myocardial Infarction Study)
trial.16 The primary end point of the study, which was
myocardial blush grade 3, was analyzed across 6 operator
groups, and it was shown to signiﬁcantly differ across
operators after adjustment for baseline and procedural
imbalances. This post-hoc analysis suggested that, even in a
controlled setting, signiﬁcant interoperator variation might
exist in the efﬁcacy of primary PCI.16 Interestingly, however,
no data on patient outcomes were available across operators
at long-term follow-up.
More recently, the operator experience, and its potential
impact on outcomes, has become a matter of debate in the
comparison of radial versus femoral access site for PCI. In the
MATRIX-Access (Minimizing Adverse Haemorrhagic Events by
TRansradial Access Site and Systemic Implementation of
angioX),12 the beneﬁt of radial versus femoral access
appeared consistent across major patient subgroups including
tertiles of the centers’ annual volume of PCI. However,
positive tests for trend were found across tertiles of the
centers’ percentage of radial PCI for both co-primary end
points and all-cause mortality at 30 days, suggesting a more-
pronounced beneﬁt of radial access in centers that did 80% or
more-radial PCI,12 and this generated great interest.13–15,24,25
Whether these differences will remain detectable also at
longer-term follow-up remains currently unclear.
All together, our results are consistent with previous
observations that operators may impact on procedural or PCI
short-term (ie, 30-day) clinical outcomes whereas such an
effect seems to vanish at time frames more remote from the
index intervention. This may reﬂect the existence in
contemporary practice of well-standardized percutaneous
techniques and improved biomedical technologies for the
treatment of patients with coronary artery disease. In this
context, factors, which are largely unrelated to the revascu-
larization procedure per se, such as adherence to and
optimal titration of secondary prevention medication as well
as comorbidities and disease progression, may affect long-
term outcomes more than procedural technical features. On
the other hand, the effect of operator on PCI outcomes
seemed to be, at best, minimal, and when operators were
stratiﬁed for their volume/experience before the trial initi-
ation, this effect disappeared. The absence of a deﬁnite
experience-outcome relationship for individual operators
should not be regarded as surprising in such a context
where centers and operators were at high volume of PCI.
However, volume per se might not be an appropriate marker
of quality (high volume may not correspond to high quality
because practice/volume by itself is of little value if the
procedure is not properly executed).2,26
Therefore, our current ﬁndings extends previous results of
the PRODIGY trial by suggesting that the impact of stent
selection or DAPT durations on ischemic and bleeding
outcomes remained consistent across study operators.
Limitations
This is a post hoc analysis sharing limitations of other not
prespeciﬁed and not powered analyses. PRODIGY is a
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3-center trial, and it cannot be excluded that, in larger trials
with many different centers and operators involved, a certain
degree of interoperator variation may exist and may have a
signiﬁcant interaction with safety and efﬁcacy end points.
Although the comparisons between operators were
adjusted for main variables, it cannot be excluded that other
confounders may affect these ﬁndings.
The number of events in some cases (ie, stroke or ST) was
too low to allow an appropriate adjusted comparison among 6
or 7 groups.
Conclusions
After adjustment for multiple patient- and procedure-related
imbalances, there was a weak signal of heterogeneity across
individual study operators for the 30-day, but not the 2-year,
main study outcomes, and no differences were observed across
operators’ past PCI volumes. Accordingly, no clear effect of the
operator was observed for the comparative efﬁcacy and safety
proﬁle of the randomized stent types or DAPT duration
regimens in our study, which has notable implications for the
external validity of the PRODIGY study results.
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 Table S1. Baseline and procedural characteristics according to operator experience. 
 
Characteristic 
More experienced 
operators  
(N=798) 
Experienced 
operators 
(N=1063) 
p-value 
Age (yr) 68.28 ± 11.52 68.01 ± 11.40 0.606 
Male 607 (76.1%) 801 (75.4%) 0.743 
Body Mass Index (kg/m2) 26.86 ± 3.84 27.40 ± 4.37 0.006 
Diabetes 190 (23.8%) 263 (24.7%) 0.663 
Insulin-dependent  52 (6.5%) 65 (6.1%) 0.772 
Hypertension 562 (70.4%) 775 (72.9%) 0.252 
Hyperlipidemia  413 (51.8%) 566 (53.2%) 0.542 
Current smoker 204 (25.6%) 252 (23.7%) 0.384 
Family history of CAD 239 (29.9%) 282 (26.5%) 0.106 
Prior MI 209 (26.2%) 289 (27.2%) 0.634 
Prior PCI  152 (19.0%) 172 (16.2%) 0.109 
Prior CABG 95 (11.9%) 95 (8.9%) 0.037 
Peripheral arterial disease 96 (12.0%) 133 (12.5%) 0.776 
Creatinine Clearance (ml/min) 76.37 ± 31.01 78.35 ± 31.47 0.175 
LVEF (%) 50.44 ± 10.24 49.90 ± 10.42 0.261 
Clinical presentation       
Stable angina pectoris 203 (25.4%) 200 (18.8%) 0.001 
ACS 595 (74.6%) 863 (81.2%) 0.001 
STEMI 136 (17.0%) 208 (19.6%) 0.184 
NSTEMI 189 (23.7%) 260 (24.5%) 0.743 
Unstable Angina 270 (33.8%) 395 (37.2%) 0.143 
Access site     <0.001 
radial 493 (61.8%) 748 (70.4%) <0.001 
femoral 154 (19.3%) 187 (17.6%) 0.364 
other or missing 151 (18.9%) 128 (12.0%) <0.001 
Angiographic features        
Multivessel Disease 567 (71.1%) 733 (69.0%) 0.333 
No. of diseased vessels     0.621 
   Single-vessel disease 231 (28.9%) 330 (31.0%) 0.333 
   Two-vessel disease 288 (36.1%) 372 (35.0%) 0.625 
   Three-vessel disease 279 (35.0%) 361 (34.0%) 0.658 
Multivessel intervention 225 (28.2%) 272 (25.6%) 0.223 
No. of treated lesions     0.012 
1 lesion 514 (64.4%) 661 (62.2%) 0.332 
2 lesions 219 (27.4%) 266 (25.0%) 0.241 
3 lesions 40 (5.0%) 90 (8.5%) 0.004 
≥4 lesions 25 (3.1%) 46 (4.3%) 0.221 
Treated vessel(s)       
LAD 384 (48.1%) 591 (55.6%) 0.001 
LCX 286 (35.8%) 306 (28.8%) 0.001 
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 Right coronary artery 285 (35.7%) 390 (36.7%) 0.697 
Left main artery 47 (5.9%) 61 (5.7%) 0.920 
Saphenous vein graft 24 (3.0%) 15 (1.4%) 0.021 
At least one complex lesion* 491 (61.5%) 743 (69.9%) <0.001 
At least one restenotic lesion 45 (5.6%) 36 (3.4%) 0.021 
Type of randomized stent     0.062 
Bare-metal stent 218 (27.3%) 259 (24.4%) 0.163 
Paclitaxel-eluting stent 212 (26.6%) 251 (23.6%) 0.159 
Zotarolimus-eluting stent 176 (22.1%) 283 (26.6%) 0.026 
Everolimus-eluting stent 192 (24.1%) 270 (25.4%) 0.516 
Number of implanted stents 1.79 ± 1.09 1.87 ± 1.23 0.118 
Overall stent length, mm 37.78 ± 26.07 39.96 ± 29.78 0.100 
Mean stent diameter, mm 3.01 ± 0.44 2.96 ± 0.45 0.011 
PCI performed by 2 or more operators 221 (27.7%) 195 (18.3%) <0.001 
CRUSADE score 27.32 ± 13.09 26.86 ± 13.06 0.456 
Randomized DAPT regimen at 30 days     0.599 
Short DAPT (6 months) 389 (48.7%) 523 (49.2%) 0.851 
Long DAPT (24 months) 392 (49.1%) 524 (49.3%) 0.963 
Not randomized 17 (2.1%) 16 (1.5%) 0.375 
p-values are chi-square test for categories, t-test for continuous variables). 
* Type B2 or C lesion according to the ACC/AHA coronary lesion classification. 
Abbreviations: ACC=American College of Cardiology; ACS= Acute Coronary Syndrome; 
AHA=American Heart Association; CABG=Coronary Artery Bypass Graft; CAD=Coronary Artery 
Disease; LAD=Left Anterior Descending Artery; LCX=Left Circumflex Artery; LVEF=Left 
Ventricle Ejection Fraction; MI=Myocardial Infarction; NSTEMI=Non-ST-Elevation Myocardial 
Infarction; PCI=Percutaneous Coronary Intervention; RCA= Right Coronary Artery; STEMI= ST-
Elevation Myocardial Infarction. 
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 Table S2. Clinical outcomes at 30 days according to operator experience. 
 
Event 
More experienced 
operators  
(N=798) 
Experienced 
operators 
(N=1063) 
p-value 
        
Primary Efficacy Endpoint        
All-cause Death, MI or CVA 89 (11.2) 110 (10.3) 0.603 
Secondary Efficacy Endpoints       
All-cause Death or MI 81 (10.2) 106 (10.0) 0.919 
All-cause Death 17 (2.1) 16 (1.5) 0.315 
Cardiovascular Death 17 (2.1) 16 (1.5) 0.315 
Stroke or TIA 10 (1.3) 6 (0.6) 0.119 
Myocardial infarction MI 70 (8.8) 93 (8.8) 1.000 
Definite ST  5 (0.6) 9 (0.9) 0.591 
Definite or Probable ST 10 (1.3) 16 (1.5) 0.652 
Definite, Probable or Possible ST 11 (1.4) 16 (1.5) 0.825 
TVR 8 (1.0) 11 (1.0) 0.950 
Safety Endpoints       
Access-site related bleeding* 9 (1.1) 11 (1.0) 0.847 
BARC classification       
Key safety endpoint - Type 2, 3 or 5 15 (1.9) 20 (1.9) 0.997 
Type 3 or 5  6 (0.8) 7 (0.7) 0.806 
TIMI classification       
   Minor 3 (0.4) 3 (0.3) 0.724 
   Major 0 (0.0) 2 (0.2) 0.996 
   Minor or major 3 (0.4) 5 (0.5) 0.761 
GUSTO classification       
Moderate 4 (0.5) 3 (0.3) 0.450 
Severe 0 (0.0) 2 (0.2) 0.996 
Moderate or severe 4 (0.5) 5 (0.5) 0.921 
Net Clinical Adverse Events (NACE)        
All-cause Death, MI, CVA or BARC 2, 3 or 5 103 (12.9) 128 (12.0) 0.596 
All-cause Death, MI, CVA or BARC 3 or 5 95 (11.9) 116 (10.9) 0.523 
Wald chisquare p-value testing the more experienced vs the experienced operators in Weibull time-
to-event regression. 
*Access-site related bleeding analyzed with Logistic regression.  
Abbreviations: BARC=Bleeding Academic Research Consortium; CVA=Cerebrovascular 
Accident; GUSTO= Global Use of Strategies to Open Occluded Coronary Arteries; MI=Myocardial 
Infarction; ST=Stent Thrombosis; TIA=Transient Ischemic Attack; TIMI=Thrombolysis in 
Myocardial Infarction; TVR=Target Vessel Revascularization.
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 Table S3. Clinical outcomes at 2 years according to operator experience. 
 
Event 
More experienced 
operators  
(N=798) 
Experienced 
operators 
(N=1063) 
p-value 
        
Primary Efficacy Endpoint        
All-cause Death, MI or CVA 157 (19.7) 222 (20.9) 0.575 
Secondary Efficacy Endpoints       
All-cause Death or MI 145 (18.2) 210 (19.8) 0.421 
All-cause Death 69 (8.7) 88 (8.3) 0.758 
Cardiovascular Death 46 (5.8) 57 (5.4) 0.694 
Stroke or TIA 21 (2.7) 26 (2.5) 0.769 
Myocardial infarction MI 99 (12.5) 144 (13.8) 0.486 
Definite ST  12 (1.6) 17 (1.6) 0.877 
Definite or Probable ST 22 (2.8) 31 (3.0) 0.849 
Definite, Probable or Possible ST 46 (5.9) 61 (5.9) 0.967 
TVR 97 (12.7) 116 (11.3) 0.409 
Safety Endpoints       
BARC classification       
Key safety endpoint - Type 2, 3 or 5 65 (8.5) 76 (7.4) 0.422 
Type 3 or 5  35 (4.6) 30 (2.9) 0.071 
TIMI classification       
   Minor 13 (1.7) 13 (1.3) 0.455 
   Major 13 (1.7) 10 (1.0) 0.189 
   Minor or major 26 (3.4) 23 (2.2) 0.149 
GUSTO classification       
Moderate 17 (2.2) 17 (1.7) 0.390 
Severe 14 (1.8) 12 (1.2) 0.260 
Moderate or severe 31 (4.0) 29 (2.8) 0.166 
Net Clinical Adverse Events (NACE)        
All-cause Death, MI, CVA or BARC 2, 3 or 5 197 (24.7) 276 (26.0) 0.618 
All-cause Death, MI, CVA or BARC 3 or 5 170 (21.3) 240 (22.6) 0.593 
Wald chisquare p-value testing the more experienced vs the experienced operators in Weibull time-
to-event regression. 
Abbreviations: BARC=Bleeding Academic Research Consortium; CVA=Cerebrovascular 
Accident; GUSTO= Global Use of Strategies to Open Occluded Coronary Arteries; MI=Myocardial 
Infarction; ST=Stent Thrombosis; TIA=Transient Ischemic Attack; TIMI=Thrombolysis in 
Myocardial Infarction; TVR=Target Vessel Revascularization.
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 Table S4. Unadjusted and adjusted hazard ratios for main clinical outcomes according to 
operator experience. 
 
Event 
Hazard Ratio 
(95% CI) 
p-value 
Adjusted Hazard 
Ratio (95% CI) 
Adjusted 
p-value 
          
At 30 days         
All-cause Death, MI or CVA 1.08 (0.81-1.42) 0.603 1.16 (0.87-1.54) 0.321 
BARC 2, 3 or 5 1.00 (0.51-1.96) 0.997 1.02 (0.51-2.04) 0.947 
All-cause Death, MI, CVA or BARC 2, 3 or 5 1.07 (0.83-1.39) 0.596 1.15 (0.88-1.50) 0.299 
All-cause Death, MI, CVA or BARC 3 or 5 1.09 (0.83-1.43) 0.523 1.18 (0.89-1.56) 0.253 
At 2 years         
All-cause Death, MI or CVA 0.94 (0.77-1.16) 0.575 0.99 (0.80-1.23) 0.945 
BARC 2, 3 or 5 1.15 (0.82-1.59) 0.422 1.17 (0.84-1.65) 0.354 
All-cause Death, MI, CVA or BARC 2, 3 or 5 0.95 (0.80-1.15) 0.618 1.00 (0.82-1.20) 0.966 
All-cause Death, MI, CVA or BARC 3 or 5 0.95 (0.78-1.15) 0.593 0.99 (0.80-1.21) 0.886 
          
Hazard ratios from Adjusted Weibull time-to-event regression comparing More experienced 
operators vs Experienced operators, adjusted for: PCI performed by two or more operators (vs. one 
operator only), age, gender, BMI, hypertension, dyslipidemia, current smoking, family history 
CAD, previous PCI, CABG, peripheral arterial disease, creatinine clearance, LVEF, ACS, femoral 
access, multivessel PCI, one or more complex lesions, one or more restenotic lesions, randomized 
stent (4 categories), total stent length, CRUSADE score.
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 Figure S1. Stratified effect of operators on the DAPT randomization by landmark approach. 
 
 
Hazard ratios from Weibull time-to-event regression on the composite of all-cause death, MI or 
CVA comparing the randomized DAPT durations and testing for effect modification by the 
Operators n (1 to 6). 
* Short DAPT randomized to 6 months of DAPT, Long DAPT randomized to 24 months of DAPT 
** Operators with less than 10 events and Other Operators are shown for completeness but not used 
for interaction testing. 
Abbreviations: CVA=Cerebrovascular Accidents; DAPT=Dual Antiplatelet Therapy; 
MI=Myocardial Infarction.
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 Figure S2. Stratified effect of operator volume of procedures (2 strata) on the DAPT and stent 
type randomizations.  
 
* ZES-S, PES and EES combined. 
Abbreviations: BMS=Bare Metal Stent; CVA=Cerebrovascular Accidents; DAPT=Dual 
Antiplatelet Therapy; DES=Drug-Eluting Stent; MI=Myocardial Infarction. 
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 Figure S3. Stratified effect of operator volume of procedures (3 strata) on the DAPT and stent 
type randomizations. 
 
 * ZES-S, PES and EES combined. 
Abbreviations: BMS=Bare Metal Stent; CVA=Cerebrovascular Accidents; DAPT=Dual 
Antiplatelet Therapy; DES=Drug-Eluting Stent; MI=Myocardial Infarction. 
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 Figure S4. Stratified effect of operator experience on the DAPT randomization. 
 
 
 
Hazard ratios from Weibull time-to-event regression on the composite of all-cause death, MI or 
CVA comparing the randomized DAPT duration or comparing the randomized stents and testing for 
effect modification by the Operator experience (More experienced or Experienced). Three-way 
interaction Operator experience x randomized DAPT (short or long) x randomized stent group 
(DES or BMS): χ = 1.05, df=1, p=0.94 
* Short DAPT randomized to 6 months of DAPT, Long DAPT randomized to 24 months of DAPT 
** ZES-S, PES and EES combined. 
Abbreviations: BMS=Bare Metal Stent; CVA=Cerebrovascular Accidents; DAPT=Dual 
Antiplatelet Therapy; DES=Drug-Eluting Stent; MI=Myocardial Infarction. 
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 Figure S5. Stratified effect of operator experience on the DAPT randomization by landmark 
approach. 
 
 
 
* Short DAPT randomized to 6 months of DAPT, Long DAPT randomized to 24 months of DAPT 
Abbreviations: BMS=Bare Metal Stent; CVA=Cerebrovascular Accidents; DAPT=Dual 
Antiplatelet Therapy; DES=Drug-Eluting Stent; MI=Myocardial Infarction. 
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